



A**All patients**


No. at risk

	0	20	40	60	80
Wildtype	223	216	199	188	80
Mutation	25	24	22	21	10




No. at risk

	0	20	40	60	80
Wildtype	244	237	225	210	88
Mutation	29	27	26	25	11

B**Subgroup: patients with adjuvant chemotherapy**


No. at risk

	0	20	40	60	80
Wildtype	69	68	63	62	29
Mutation	13	13	13	12	5




No. at risk

	0	20	40	60	80
Wildtype	80	78	73	71	32
Mutation	16	15	15	15	6

C**Subgroup: patients without adjuvant chemotherapy**

No. at risk

	0	20	40	60	80
Wildtype	128	124	113	106	47
Mutation	12	11	9	9	5



No. at risk

	0	20	40	60	80
Wildtype	134	130	124	114	50
Mutation	13	12	11	10	5

Figure S2. Survival analyses. Kaplan-Meier plots stratified by *BRCA1/2* mutation status for (A) the entire study cohort, (B) for the subgroup that received adjuvant chemotherapy, and (C) for the subgroup without adjuvant chemotherapy.